"I think we noted previously in discussions, whether that was Meet Novartis Management or other calls, where we were using a digital endpoint. And we were having really good discussions with the agency on using this aggressive approach using this digital end point. At the end of the year last year, they came back and they noted that they wanted to still use the same endpoint as previously, which is the part \u2013 biopsy-proven acute rejection. Having that as feedback, we felt like we wanted to ensure that we have a path forward, which would be a full Phase III, so \u2013 which would be the same time lines as developing your traditional transplant drugs."